Oncotarget

Meta-Analysis:

Diagnostic efficacy of long non-coding RNA MALAT-1 in human cancers: a meta-analysis study

Yan Chen, Zhenzhou Xiao, Minhua Hu, Xiaoli Luo and Zhaolei Cui _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:102291-102300. https://doi.org/10.18632/oncotarget.21013

Metrics: PDF 681 views  |   HTML 1045 views  |   ?  


Abstract

Yan Chen1, Zhenzhou Xiao1, Minhua Hu1, Xiaoli Luo1 and Zhaolei Cui1

1Laboratory of Biochemistry and Molecular Biology Research, Fujian Provincial Key Laboratory of Tumor Biotherapy, Department of Clinical Laboratory, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China

Correspondence to:

Zhaolei Cui, email: cuileidizi@fjmu.edu.cn

Keywords: MALAT-1, cancer, diagnosis, meta-analysis

Received: June 19, 2017     Accepted: August 26, 2017     Published: September 18, 2017

ABSTRACT

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) is one kind of long non-coding RNAs (lncRNAs) that has been recognized as a hallmark of the onset and development of several carcinomas. This study seek to meta-analyze the overall diagnostic efficacy of elevated MALAT-1 expression profile for human cancers. Studies on the diagnostic performance of MALAT-1 in cancers were retrieved by searching the online databases. The combined effect sizes were summarized using a bivariate meta-analysis model. Impacts of publication bias on the pooled effect sizes were assessed using “Duval and Tweedie nonparametric trim and fill method”. Sensitivity analysis and meta-regression test were applied to deeply trace the heterogeneity sources among eligible studies. A total of 14 studies with 1342 cancer cases were included. The combined effect sizes showed that MALAT-1 expression profiling conferred an estimated sensitivity of 0.69 (95% CI: 0.62–0.75) (I2 = 84.01%, P < 0.001), specificity of 0.85 (95% CI: 0.79–0.90) (I2 = 87.95%, P < 0.001) and AUC (area under curve) of 0.83 in distinguishing cancer patients from noncancerous contrasts. Moreover, stratified analysis depending on cancer type manifested that elevated MALAT-1 harbored a promising efficacy in the diagnosis of pulmonary tumors (AUC = 0.90), digestive system tumors (AUC = 0.84), gynecologic cancers (AUC = 0.84) and nasopharyngeal carcinoma (AUC = 0.84), particularly in confirming the subtype of squamous carcinoma (AUC = 0.91) and non-small cell lung carcinoma (AUC = 0.88) in lung cancer. Other analyses based on test matrix and ethnicity also presented robust results. Collectively, elevated MALAT-1 could be developed as an auxiliary molecular marker to aid in cancer diagnosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21013